Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal cancer[1][2].
Ensituximab (NPC-1C) 是一种嵌合 IgG1 单克隆抗体,在结合其靶标后促进抗体依赖性细胞的细胞毒性,MUC5AC 是一种肿瘤特异性变体,一种由结直肠癌 (CRC) 和胰腺癌特异性表达的抗原[1]。
[1]. Richard D Kim, et al. Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. Clin Cancer Res. 2020 Jul 15;26(14):3557-3564.
[2]. Julian A Marin-Acevedo, et al. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 2018 Jan 12;11(1):8.
















